The therapeutic effect of pemigatinib

Pemigatinib (Pemigatinib) is a cancer drug used to treat adults with cholangiocarcinoma (biliary tract or cholangiocarcinoma), in which the cancer cells have an abnormal form of a receptor (target) on their surface called FGFR2. Pemetinib is used when the cancer has spread to other parts of the body or cannot be removed with surgery, and has worsened after previous treatment with at least one cancer drug. Pemetinib is considered effective in patients with biliary tract cancer who have progressed after at least one prior line of therapy and who have no other authorized treatments. Patients can tolerate the side effects of medications with close monitoring and treatment. The European Medicines Agency decided that the benefits of pemetinib outweighed its risks, so it could be authorized for use.